Novo Nordisk A/S (NVO)

NYSE: NVO · Real-Time Price · USD
68.93
-2.08 (-2.93%)
At close: Jul 11, 2025, 4:00 PM
68.86
-0.07 (-0.10%)
After-hours: Jul 11, 2025, 7:59 PM EDT
-2.93%
Market Cap 305.41B
Revenue (ttm) 43.92B
Net Income (ttm) 15.16B
Shares Out 4.44B
EPS (ttm) 3.40
PE Ratio 20.15
Forward PE 16.30
Dividend $1.18 (1.71%)
Ex-Dividend Date Mar 31, 2025
Volume 6,522,057
Open 69.74
Previous Close 71.01
Day's Range 68.53 - 69.89
52-Week Range 57.00 - 143.49
Beta 0.22
Analysts Buy
Price Target 112.00 (+62.48%)
Earnings Date Aug 6, 2025

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]

Sector Healthcare
Founded 1923
Employees 77,349
Stock Exchange NYSE
Ticker Symbol NVO
Full Company Profile

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK Financial Statements

Analyst Summary

According to 3 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $112.0, which is an increase of 62.48% from the latest price.

Price Target
$112.0
(62.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Novo Nordisk: The Market Doesn't Get It

Novo Nordisk remains dominant in diabetes and obesity care, with strong growth and expanding market share despite recent investor concerns. The company's pipeline, especially the oral GLP-1 and Alzhei...

19 hours ago - Seeking Alpha

3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies

I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. Three companies—Pfizer, BMW, and Singapore Airlines—currently me...

Other symbols: ACNDALFDXHDJNJKOLOW
1 day ago - Seeking Alpha

Novo Nordisk's Canadian drug patent lapses, opening market for Hims & Her Health

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth company, among others, will now be allowed to make exact copies of Novo's ...

Other symbols: HIMS
2 days ago - CNBC Television

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.

Other symbols: HIMS
2 days ago - CNBC

Novo Nordisk: Reclaiming Market Share

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects due to rising global demand and a robust pipeline. Recent stock weakness is overdone; valuation models s...

3 days ago - Seeking Alpha

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.

Other symbols: BMYGILDJNJPFEVRTX
3 days ago - CNBC

Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving...

3 days ago - Reuters

Italy set to speed through $2.3 billion Novo Nordisk investment

Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its promised 2 billion-euro ($2.34 billion) investment in a factory south of Rome.

4 days ago - Reuters

Novo Nordisk's Sell-Off Has Gone Too Far

Novo Nordisk's recent sell-off is overdone; current fears around pricing and CagriSema are temporary, creating a compelling buying opportunity. The company's fundamentals remain strong, with robust sa...

5 days ago - Seeking Alpha

Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever

Novo Nordisk's fundamentals remain robust despite recent share price weakness, with strong sales and profit growth as well as a well-established pipeline. Concerns over CEO transition and compounding ...

10 days ago - Seeking Alpha

Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share

Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.

10 days ago - CNBC Television

Insight: How Novo Nordisk misread the US market for its weight loss sensation

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable ...

10 days ago - Reuters

Health Rounds: Novo Nordisk's semaglutide may help some with type 1 diabetes

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

14 days ago - Reuters

Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

15 days ago - WSJ

Novo Nordisk ties up with WeightWatchers to sell Wegovy

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, Wegovy, starting July 1.

15 days ago - Reuters

Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on ...

15 days ago - PRNewsWire

Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy

Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk...

Other symbols: LLY
16 days ago - Reuters

Weight loss and diabetes jabs linked to potentially fatal side effect

Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.

Other symbols: LLY
16 days ago - Skynews

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $NVO--NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm.

16 days ago - Business Wire

The Best European Stocks to Buy

European stocks are cheaper than their U.S. counterparts, and there are plenty of high-quality companies to choose from. Here's how you can find them.

Other symbols: SPOTUL
16 days ago - Kiplinger

Hims & Hers stock plummets after Novo Nordisk ends partnership over ‘knockoff' Wegovy

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers' ...

Other symbols: HIMS
17 days ago - Fast Company

Novo Nordisk launches blockuster weight-loss drug Wegovy in India

Danish drugmaker Novo Nordisk officially launched its blockbuster weight-loss drug Wegovy on Tuesday as a once-a-week injection in India.

18 days ago - Reuters

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

18 days ago - CNBC Television

EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label

Novo Nordisk said on Monday the European drugs regulator has adopted a positive opinion for an update of the Ozempic label to include peripheral artery disease.

18 days ago - Reuters

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an up...

18 days ago - GlobeNewsWire